WB, IP, IHC-P, FC-L
H
Endogenous
55, 65
Rabbit IgG
#Q14627
3598
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:100 - 1:400 |
| Flow Cytometry (Live) | 1:50 |
Storage
For a carrier free (BSA and azide free) version of this product see product #68588.
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human IL-13RA2/CD213a2 protein.
Background
Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).
IL-13 receptor alpha-2 (IL-13RA2/CD213a2) is a type-I monomeric transmembrane glycoprotein and component of the IL-4/IL-13 receptor system. Research studies have shown that IL-13RA2 controls IL-13 signaling by serving as a high affinity decoy receptor for IL-13, but not IL-4, in a variety of cellular contexts (4,5). Some studies, however, have suggested that signaling through IL-13RA2 expressed on immunosuppressive myeloid cells facilitates tumor immune evasion through the production of TGF-β (6,7).
IL-13RA2 displays a highly restricted expression pattern in normal human tissues, which positions this receptor as a potentially novel therapeutic target for multiple types of solid tumors (8-10). Indeed, research studies have shown that IL-13RA2 is highly over expressed in glioblastomas (11), which has prompted investigation of different IL-13RA2-directed immunotherapies to treat this cancer (12-14).
- Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21.
- De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35.
- Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87.
- Yoshikawa, M. et al. (2003) Biochem Biophys Res Commun 312, 1248-55.
- Bernard, J. et al. (2001) Lab Invest 81, 1223-31.
- Fichtner-Feigl, S. et al. (2006) Nat Med 12, 99-106.
- Fichtner-Feigl, S. et al. (2008) Cancer Res 68, 3467-75.
- Debinski, W. and Gibo, D.M. (2000) Mol Med 6, 440-9.
- Taguchi, A. et al. (2014) Cancer Res 74, 4694-705.
- Beard, R.E. et al. (2013) Clin Cancer Res 19, 4941-50.
- Jarboe, J.S. et al. (2007) Cancer Res 67, 7983-6.
- Brown, C.E. et al. (2015) Clin Cancer Res 21, 4062-72.
- Brown, C.E. et al. (2012) Clin Cancer Res 18, 2199-209.
- Mintz, A. et al. (2008) Cancer Biother Radiopharm 23, 581-9.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) FC-L: Flow Cytometry (Live)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.